Indication intelligence, analysis and sector perception

RegMed Investors (RMi): BrainStorm Cell Therapeutics (BCLI) Prices $4 Million Registered Direct Offering (RDO) at $0.36 of 11.11 million shares and 16.66 million warrants at $0.36

June 27, 2024

BCLI is trading at $0.34 or -$0.0451 or -$11.56% Maxim Group LLC is acting as the sole placement agent for the offering. … Walk away …

RegMed Investors (RMi) Research/Financing Note: Ultragenyx Pharmaceutical (RARE) priced offering of 7,435,898 shares at $39.00 per share.

June 14, 2024

RARE closed down -$1.52 at $43.12 with a -$1.94 or -4.50% to $41.18 The offering is expected to close on or about 6/17/24, subject to satisfaction of customary closing conditions.  J.P. Morgan, Goldman Sachs & Co. LLC, BofA Securities, and TD Cowen are acting as joint book-running managers for the offering.  

RegMed Investors (RMi) - Q1/24 Cell and Gene Therapy Earnings Scorecard Results

May 20, 2024

A scorecard of earnings releases of covered companies -  The current LPS (loss per share) or net income, revenue, cash positions i.e. "runways" is a reflection of this universe's investing "status". 30 of 35